Piper Sandler has initiated coverage of CytomX Therapeutics (CTMX, Financial) with an optimistic outlook, assigning an Overweight rating to the stock. The investment firm has adjusted its price target to $2.50, previously set at $3.25. The revised target reflects current market estimations as the company progresses through critical clinical trials.
CytomX is actively advancing its Phase I dose-escalation study of CX-2051, targeting metastatic colorectal cancer. The seventh cohort is currently being enrolled, with initial data expected by the second quarter of 2025. The study aims to validate the safety of this masked EpCAM ADC, where any signs of efficacy, such as stable disease, would represent a significant breakthrough for patients in later stages of colorectal cancer.
In addition to this, CytomX is exploring the therapeutic potential of Probody masked interferon-alpha2b, known as CX-801, in the treatment of metastatic melanoma. The Phase I dose-escalation trial for this candidate is progressing, with preliminary pharmacodynamic data anticipated in the latter half of 2025. Efficacy data from this study is expected to follow in 2026.
The advancements in these trials could play a pivotal role in CytomX's future, as successful outcomes may not only boost the stock's value but also provide new therapeutic options for cancer patients. Piper Sandler's analysis underscores the potential of CytomX's innovative approaches in the oncology field.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for CytomX Therapeutics Inc (CTMX, Financial) is $4.75 with a high estimate of $8.00 and a low estimate of $2.50. The average target implies an upside of 792.02% from the current price of $0.53. More detailed estimate data can be found on the CytomX Therapeutics Inc (CTMX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, CytomX Therapeutics Inc's (CTMX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CytomX Therapeutics Inc (CTMX, Financial) in one year is $3.43, suggesting a upside of 544.13% from the current price of $0.5325. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CytomX Therapeutics Inc (CTMX) Summary page.
